129872-50-0

Basic information

• Product Name: 4-(Methylsulfonylamino)benzylamine
• Synonyms: MethanesulfonaMide, N-[4-(aMinoMethyl)phenyl]-
• CAS NO: 129872-50-0
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.2581
• Product Categories: Amines and Anilines;Boron, Nitrile, Thio,& TM-Cpds
• Mol File: 129872-50-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 255-257 °C
• Boiling Point: 353.9 °C at 760 mmHg
• Flash Point: 167.8 °C
• Appearance: /
• Density: 1.335 g/cm³
• PKA: 7.59±0.10(Predicted)
• CAS DataBase Reference: 4-(Methylsulfonylamino)benzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylsulfonylamino)benzylamine(129872-50-0)
• EPA Substance Registry System: 4-(Methylsulfonylamino)benzylamine(129872-50-0)

Safety Data

• Hazardous Substances Data: 129872-50-0(Hazardous Substances Data)

Usage

General Description

4-(Methylsulfonylamino)benzylamine, also known as MSAB, is a chemical compound with the molecular formula C8H12N2O2S. It is a white to off-white crystalline powder with a molecular weight of 192.26 g/mol. MSAB is a derivative of benzylamine, containing a methylsulfonylamino group. It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. MSAB has potential applications in the treatment of various diseases and as a building block in the development of new drugs. Additionally, it is also used in the research and development of chemical processes and synthesis.

Upstream product

• 36268-67-4 4-((methylsulfonyl)amino)benzonitrile 
• 238427-63-9 tert-butyl N-[[4-(methanesulfonamido)phenyl]methyl]carbamate 
• 873-74-5 4-Aminobenzonitrile 
• 94838-58-1 tert-butyl 4-nitrobenzylcarbamate 
• 94838-55-8 tert-butyl (4-aminobenzyl)carbamate 
• 18600-42-5 4-nitrobenzylamine hydrochloride 

Downstream Products

• 910534-86-0 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-propionamide 
• 910534-88-2 2-(4-t-butyl-benzyl)-N-(4-methanesulfonylamino-benzyl)-butyramide 
• 515153-00-1 C₂₅H₂₄N₄O₄S 
• 1375102-86-5 C₂₇H₃₉N₃O₄S₂ 
• 1375102-76-3 C₂₆H₃₇N₃O₄S₂ 
• 1375102-66-1 C₂₈H₄₁N₃O₄S₂ 
• 1227946-71-5 3-[5,6-bis(methyloxy)-2-pyridinyl]-N-({4-[(methylsulfonyl)amino]phenyl}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-6-carboxamide 
• 1207961-00-9 N-(4-[3-(4-ethyldimethylsilanylbenzyl)thioureidomethyl]phenyl)methanesulfonamide 
• 1207960-97-1 N-(4-[3-(4-trimethylsilanylbenzyl)thioureidomethyl]-phenyl)methanesulfonamide 
• 900144-19-6 C₂₃H₂₄N₆O₅S₂ 
• 900144-20-9 C₂₂H₂₂N₆O₅S₂ 
• 900145-06-4 N-{4-[(3-hydrazinocarbonyl-pyridin-2-ylamino)-methyl]-phenyl}-methanesulfonamide 

Relevant articles and documents

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists

GSK805 (1) is a potent RORγt inverse agonist, but a drawback of 1 is its low solubility, leading to a limited absorption in high doses. We have explored detailed structure-activity relationship on the amide linker, biaryl and arylsulfonyl moieties of 1 trying to improve solubility while maintaining RORγt activity. As a result, a novel series of carboxyl-containing biaryl urea derivatives was discovered as potent RORγt inverse agonists with improved drug-like properties. Compound 3i showed potent RORγt inhibitory activity and subtype selectivity with an IC50 of 63.8 nM in RORγ FRET assay and 85 nM in cell-based RORγ-GAL4 promotor reporter assay. Reasonable inhibitory activity of 3i was also achieved in mouse Th17 cell differentiation assay (76percent inhibition at 0.3 μM). Moreover, 3i had greatly improved aqueous solubility at pH 7.4 compared to 1, exhibited decent mouse PK profile and demonstrated some in vivo efficacy in an imiquimod-induced psoriasis mice model.

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (β-blocking) effects with use of in vitro and in